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Protein and chemotherapy profiling of extracellular vesicles
harvested from therapeutic induced senescent triple negative
breast cancer cells
EL Kavanagh1,9, S Lindsay1,9, M Halasz2,3, LC Gubbins1, K Weiner-Gorzel1, MHZ Guang1, A McGoldrick1, E Collins1, M Henry4,
A Blanco-Fernández1, PO' Gorman5, P Fitzpatrick6, MJ Higgins7, P Dowling8 and A McCann1,3
Triple negative breast cancer (TNBC) is an aggressive subtype with relatively poor clinical outcomes and limited treatment options.
Chemotherapy, while killing cancer cells, can result in the generation of highly chemoresistant therapeutic induced senescent (TIS)
cells that potentially form stem cell niches resulting in metastases. Intriguingly, senescent cells release significantly more
extracellular vesicles (EVs) than non-senescent cells. Our aim was to profile EVs harvested from TIS TNBC cells compared with
control cells to identify a potential mechanism by which TIS TNBC cells maintain survival in the face of chemotherapy. TIS was
induced and confirmed in Cal51 TNBC cells using the chemotherapeutic paclitaxel (PTX) (Taxol). Mass spectrometry (MS) analysis of
EVs harvested from TIS compared with control Cal51 cells was performed using Ingenuity Pathway Analysis and InnateDB programs.
We demonstrate that TIS Cal51 cells treated with 75 nM PTX for 7 days became senescent (senescence-associated β-galactosidase
(SA-β-Gal) positive, Ki67-negative, increased p21 and p16, G2/M cell cycle arrest) and released significantly more EVs (P= 0.0002)
and exosomes (P= 0.0007) than non-senescent control cells. Moreover, TIS cells displayed an increased expression of the multidrug
resistance protein 1/p-glycoprotein. MS analysis demonstrated that EVs derived from senescent Cal51 cells contained 142 proteins
with a significant increased fold change compared with control EVs. Key proteins included ATPases, annexins, tubulins, integrins,
Rabs and insoluble senescence-associated secretory phenotype (SASP) factors. A fluorescent analogue of PTX (Flutax-2) allowed
appreciation of the removal of chemotherapy in EVs from senescent cells. Treatment of TIS cells with the exosome biogenesis
inhibitor GW4869 resulted in reduced SA-β-Gal staining (P= 0.04). In summary, this study demonstrates that TIS cells release
significantly more EVs compared with control cells, containing chemotherapy and key proteins involved in cell proliferation,
ATP depletion, apoptosis and the SASP. These findings may partially explain why cancer senescent cells remain viable despite
chemotherapeutic challenge.
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INTRODUCTION
In Ireland, ~ 2883 women will be diagnosed annually with breast
cancer, representing the highest incidence of all female cancers in
Ireland, with 10–15% described as triple negative breast cancer
(TNBC).1 TNBC is characterised by its aggressive behaviour and
lack of expression of the oestrogen, progesterone and HER2
receptors. This results in TNBCs not being amenable to endocrine
and trastuzumab-based therapies, with conventional cytotoxic
therapies such as the chemotherapeutic paclitaxel (PTX) (Taxol)
the only option.2 TNBC is further characterised by early onset and
poor prognosis,3 with TNBC tumours being at a higher risk for
subsequent tumour recurrence4 owing to its chemoresistant
biology. Moreover, when TNBC relapses, it usually presents as
distant metastases, which tend to have central nervous system
involvement, rather than local, more treatable metastases.5
The chemotherapeutic PTX (Supplementary Figure 1A) prefer-
entially binds to the beta subunit of tubulin with high affinity and
enhances the polymerisation of tubulin to stable microtubules.
This stabilisation means that depolymerisation cannot take place,
the cells are unable to form the correct mitotic spindle and as a
result cells are arrested in the G2/M phase of mitosis.6 Although
the goal of chemotherapy is to induce tumour cell death via
apoptosis, paradoxically, tumour cells can maintain viability in
response to chemotherapy, by undergoing alternative fates such
as therapeutic induced senescence (TIS), resulting in the ability
of tumour cells to successfully evade apoptosis.7 Increased
expression of p21, p16 and senescence-associated β-galactosidase
(SA-β-Gal) activity are well-established markers of senescent
cells.8,9
Senescent cells although being metabolically active are also
proliferatively incompetent.10 Therefore, chemotherapies such as
PTX, with preferential efficacy on dividing cells, are less likely
to induce apoptotic cell death.11 Moreover, senescent cells
secrete the senescence-associated secretory phenotype (SASP);
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a secretome known to be associated with cancer-promoting
phenomenon such as chronic inflammation, angiogenesis, cell
proliferation and cell invasion.12 Importantly, Demaria et al.13 have
shown using a mouse model that TIS promotes an inflammatory
environment conducive to metastases and that removal of
senescent cells after chemotherapy can prevent or delay cancer
recurrence and metastases. Intriguingly, senescent cells produce
more extracellular vesicles (EVs) than non-senescent cells facilitat-
ing their continued engagement with the cellular milieu both
locally and distally.14
EVs are released by multiple cell types and can be found in
blood, urine, serum and amniotic fluid.15 The term EVs encom-
passes a range of different subsets of lipid bilayer vesicles
including vesicles of ~ 50–150 nm diameter termed exosomes.
Exosomes are released by most cells upon the fusion of
multivesicular bodies with the plasma membrane.16,17 Exosomes
are characterised by a variety of markers including the tetra-
spanins (CD63, CD9 and CD81), heat shock proteins (HSP70) and
multivesicular body formation proteins (for example, TSG101).18
It is well established that tumour exosomes comprise a large
population of total EVs in the blood of cancer patients.19
Therefore, the profiling of these EVs as circulating biomarkers in
a patient’s liquid biopsy is feasible. In addition, EVs can transmit
proteins, nutrients and RNA from one cell to another thereby,
having a functional effect on recipient cells.20 Moreover, EVs have
an integral role in intercellular communication in the TME,21 can
propagate the chemoresistant phenotype and establish metastatic
niches.22,23 EVs also facilitate the removal of misfolded proteins or
metabolic waste products that are harmful to the cell.
In relation to drug treatments and chemoresistance, EVs have
been shown to neutralise targeted antibody based drugs
such as trastuzumab/Herceptin, which targets HER2. Specifically,
HER2-overexpressing breast carcinoma cell lines release EVs
containing the HER2 protein, which preferentially sequesters
trastuzumab, leading to a decreased drug concentration and
attenuated interaction of trastuzumab with its intended HER2+
cancer cell target.24 EVs have also been shown to confer drug
resistance in a paracrine manner through the EV-mediated
transfer of the multidrug resistance protein 1/p-glycoprotein
(MDR1/P-gp) from a docetaxel-resistant breast cancer cell line to
its sensitive counterpart.25 Moreover, cancer cells can export
chemotherapeutics in EVs, thereby reducing the intracellular drug
concentration. In this regard, it has been shown that cisplatin-
resistant ovarian carcinoma cell-derived EVs contain more cisplatin
Figure 1. Confirmation of therapeutic induced senescence (TIS) in Cal51 triple negative breast cancer (TNBC) cells treated with 75 nM
paclitaxel (PTX) for seven days. (a,i) Cal51 treated with 75 nM PTX for 1 week seeded at 100 000 cells/well. Cells were stained using the
SA-β-Gal staining kit (Cell Signalling) with 5 mg/ml X-gal. Scale bars represent 20 μm. (a,ii) The percentage of positive SA-β-Gal staining was
normalised to the cell count in each condition and shown in log scale (β-Gal % positivity 77%± 5.204). (b) Cal51 TNBC cells seeded at 100 000
cells/ml, treated with 75 nM PTX for 1 week to induce senescence followed by immunohistochemical (IHC) staining for the proliferation marker
Ki67, (i) negative IHC control (ii) Ki67 staining evident in proliferating cells and absent in the larger senescent cell (white arrow). Scale bars
represent 50 μm. (c) Cal51 cells were treated with 50 nM and 75 nM PTX for 1 week. SDS–PAGE western blotting was performed using a 12% gel
for p16, p21 and GAPDH. (d) Cal51 TNBC cells treated with PTX for 1 week undergo a G2/M cell cycle arrest. (d,i) Control Cal51 TNBC cell cycle
profile. (d,ii) TIS Cal51 TNBC cell cycle profile. Cells were stained using RNase A 0.2 mg/ml and PI 50 μg/ml. All values are expressed as the
mean of three independent experiments± s.e.m. The limit of ± 1 skewness was set as normal distribution. Skewed data were transformed to
Y= Log(Y) to fit a normal distribution. Results were analysed using the Student’s t-test with significant differences having a *P⩽ 0.05,
**P⩽ 0.01, ***P⩽ 0.001.
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in comparison with cisplatin sensitive ovarian carcinoma
cell-derived EVs.26
In light of the ability of chemotherapy to induce viable TIS
cancer cells, and the documented preponderance of EV release
from senescent compared with non-senescent cells, the overall
aim of this study was to investigate the chemotherapy and protein
content of EVs derived from TIS cancer cells and determine
whether the resultant profiles may partially explain why
cancer senescent cells remain viable despite chemotherapeutic
challenge.
RESULTS
PTX induces senescence in Cal51 TNBC cells
The TIS model comprised of Cal51 TNBC cells treated with 75 nM
PTX for 7 days. TIS was appreciated using four routinely
used markers of senescence: (1) positive SA-β-Gal activity and
characteristic large flat morphology of senescent cells (Figures 1a),
(2) absence of Ki67 staining (Figure 1b) (3) sodium dodecyl
sulphate polyacrylamide gel electrophoresis western blot
appreciation of p21 and p16 overexpression (Figures 1c) and (4)
a G2/M cell cycle arrest (Figure 1d).
TIS cells release significantly more EVs than control cells
EVs were isolated from cells by differential centrifugation unless
otherwise stated. Isolation of EVs was confirmed using nano-
particle tracking analysis (NTA) measuring the concentration and
size of the particles (Figure 2a). Control and TIS EVs displayed
average modal sizes of 125 nm and 122 nm, respectively. TIS cells
released significantly more EV (P= 0.0002) and exosome
(P= 0.0007) fractions compared with control cells (Figure 2b).
EVs were confirmed to be calnexin-negative (negative control),
CD63- and HSP70-positive (positive control) by sodium dodecyl
sulphate polyacrylamide gel electrophoresis western blotting
(Figure 2c).
TIS cells maintain viability via the upregulation of MDR1/P-gp
The TIS model was further investigated for the expression of the
multidrug resistance/p-glycoprotein (MDR1/P-gp). TIS Cal51 cells
Figure 2. TIS Cal51 cells release significantly more EVs than control cells. (a) EVs were isolated using ultracentrifugation and profiles for both
control and TIS EVs were recorded using NTA (NanoSight NS300 Malvern). (b) Particle per ml concentrations of EVs sized 0–995 nm and
exosomes sized 45–145 nm were obtained using NTA and normalised to the cell count. (c) SDS–PAGE western blotting analyses were carried
out for the EV markers CD63 and HSP70. Note, owing to the known glycosylation of CD63, band sizes of between 53 and 70 kDa are observed.
Calnexin was used as a negative control as it represents an ER protein whose absence ensures for EV enrichment of endocytic origin. All values
are expressed as the mean of three independent experiments± s.e.m. The limit of ± 1 skewness was set as normal distribution. Skewed data
were transformed to Y= Log(Y) to fit a normal distribution. Results were analysed using the Student’s t-test with significant differences having
a *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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treated with 75 nM PTX for 7 days resulted in a significant
increased expression of MDR1/P-gp in the whole-cell lysates,
compared with control Cal51 cells (P= 0.04). For the EV fraction,
those derived from TIS cells demonstrated lower amounts of
MDR1/P-gp compared with those derived from control Cal51 cells
(P= 0.04) (Figure 3).
TIS cells maintain viability via the removal of key proteins in
their EVs
A proteomic study of the contents of EVs isolated from TIS
and control cells, demonstrated that EVs derived from TIS
Cal51 cells contained 142 proteins with a significant increased
fold change compared with EVs derived from non-senescent cells
(Supplementary Table 1). Key proteins of interest shown to be
significantly higher in abundance in EVs from TIS Cal51 cells
compared with control cells are displayed in Table 1. These were
annexin V; which has a role in apoptosis, chemoresistance and
metastasis, Na/K ATPase; an ion channel involved in the depletion
of cellular ATP levels and α-tubulin; a central part of the
cytoskeleton targeted by PTX. Western blot analyses confirmed
a significant increased abundance of Annexin V (P= 0.03), Na/K
ATPase (P= 0.03) and α-tubulin (P= 0.04) in EVs derived from
senescent Cal51 cells compared with EVs derived from control
cells, corroborating the mass spectrometry (MS) data (Figure 4).
The EV proteomic analysis also identified higher levels of insoluble
SASP proteins in the EVs derived from TIS cells compared with
controls (Table 1). Specifically, fibronectin, collagens alpha-1 (V)
and alpha-2 (IV) and laminin subunits alpha-5 and beta-1.27
Pathway analysis of the contents of the TIS EVs using Ingenuity
pathway analysis (IPA) revealed the following pathways; remodel-
ling of epithelial adherans junctions, EIF2 signalling, breast cancer
regulation by stathmin 1 (Figures 5a and c, Supplementary
Figure 2), phagosome maturation and epithelial adherens junction
signalling pathways. Interestingly, InnateDB database analysis
demonstrated that the stathmin and breast cancer resistance to
anti-microtubule agent’s pathway was the second most common
pathway in which the proteins from our data set are involved.
Pathway analysis of the contents of control EVs using IPA
identified the following pathways; clatherin-mediated endocytosis
signalling, systemic lupus erythematosus signalling, LXR/RXR
(liver X receptor/retinoid X receptor) activation, atherosclerosis
signalling and FXR/RXR (farnesoid X receptor/retinoid X receptor)
activation (Figure 5b). IPA of proteins present in a higher
abundance in EVs derived from TIS Cal51 cells revealed that 69
out of 142 proteins are involved in cell growth and proliferation.
The 69 proteins displayed a common function as predicted
activators of cell proliferation (Figure 5d).
TNBC cells treated with the PTX analogue Flutax-2, release EVs
containing Flutax-2
Flutax-2 contains an Oregon Green 488 fluorescent label attached
to the 7’-carbon of the PTX, which permits selective binding of the
probe to microtubules (Supplementary Figure 1B). Cells were
treated with either 75 nM PTX or 750 nM Flutax-2. Nanoparticle
tracking analysis (NTA) (Figure 6a) and western blot analyses
confirmed enrichment for EVs (Figure 6b), SA-β-gal quantification
confirmed successful senescence induction (Figure 6c). NTA
quantification demonstrated a significant increase in the particles
per ml of both EVs (P= 0.03) (Figure 6d) and exosome subfractions
(P= 0.04) (Figure 6e) isolated from Flutax-2 and PTX-treated cells
compared with non-treated control cells. EVs were subsequently
sonicated to break open the membranes allowing fluorescence to
be read on a plate reader at 488 nm. Fluorescent microscopy
confirmed Flutax-2 uptake into Cal51 cells (Figure 6f). Figure 6g
demonstrates significantly higher levels of fluorescence detected
in EVs derived from Flutax-2-treated cells.
Treatment of Cal51 TNBC cells with the exosome biogenesis
inhibitor GW4869
Cal51 cells were treated ± 75 nM PTX for 7 days. Cells were then
treated for a further 48 h ±GW4869. Treatment of TIS cells with
Figure 3. MDR1/P-gp profiling of control and therapeutic induced senescent (TIS) Cal51 cells. TIS (PTX) and non-treated control (Ctrl)
Cal51 cells were SDS–PAGE western blotted for MDR1/P-gp expression. Calnexin and CD63 were used as loading controls for the whole-cell
lysates (WCLs) and EVs respectively. Densitometry was undertaken using Image J software (Fiji). All values are expressed as the mean of three
independent experiments± s.e.m. The limit of ± 1 skewness was set as normal distribution. Skewed data were transformed to Y= Log(Y) to fit
a normal distribution. Results were analysed using the Student’s t-test with significant differences having a *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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GW4869 lead to a significant reduction in SA-β-gal staining
(P= 0.04) compared with TIS cells treated with control vehicle
alone (Figure 7a). There was a non-significant trend (P= 0.12)
towards a reduction in the number of exosomes released from TIS
cells treated with GW4869, gating specifically the 45–145 nm size
(Figure 7b). TIS cells maintained p21 upregulation in response to
GW4869 and EV isolation was confirmed using western blot
analyses (Figure 7c).
Figure 7d (i) represents a growth curve of all four conditions
(control plus GW4869, control minus GW4869, PTX plus GW4869
and PTX minus GW4869) over a 14-day time course. PTX treatment
for 7 days induced TIS in Cal51 cells. These cells were
subsequentually treated with GW4869 on day 7 and cells were
enumerated on days 9, 11 and 14 following this treatment.
GW4869-treated TIS cells displayed a significant reduction in cells
per ml on days 9 (P= 0.007), 11 (P= 0.04) and 14 (P= 0.05)
compared with TIS cells treated with control vehicle alone
(Figure 7d (ii) and E).
In summary, PTX induces senescence in Cal51 TNBC cells with a
concomitant upregulation of MDR1/P-gp. TIS cells release
significantly more EVs compared with control cells, which not
only contain the PTX analogue (Flutax-2) but in addition,
key proteins involved in cell proliferation, ATP depletion, apoptosis
and the SASP. The exosome biogenesis inhibitor GW4869 results
in a reduction in the number of SA-β-gal-positive cells and lowers
the proliferation rate of TIS cells (Figure 7f).
DISCUSSION
Chemotherapy such as doxorubicin, has been shown to induce TIS
in both p53 wild-type and p53 mutant cell lines.28 Here we
demonstrate induction of TIS in the p53 wild-type TNBC cell line
Cal51 using the chemotherapeutic PTX. Clinically, TIS occurs in
breast tumour biopsies from patients who received neoadjuvant
chemotherapy were 41% positive for SA-β-Gal activity.29 This
suggests that TIS is a novel detrimental mechanism of breast
cancer cell survival against chemotherapy. Our data show that
the MDR1/P-gp drug efflux pump is upregulated in TIS cells
accompanied with a marked increase in p21 expression. Similar to
previous studies MDR1/P-gp is detectable in our EV fractions with
lower levels in TIS EVs, possibly referring to the retention of this
efflux pump by the parent cells in their chemotherapeutic stressed
condition. Mechanistically, it is known that the E2F-associated
phosphoprotein stimulates the MDR1/P-gp promoter, leading to
the upregulation of MDR1/P-gp in a p21-dependent manner.30
Interestingly, MDR1/P-gp has also been shown to transfer
resistance to docetaxel via EVs in breast and prostate cancer
cells.25,31
The higher abundance of EVs in the blood of breast cancer
patients with stage IV disease has previously been reported.32 Our
study has found that TIS cells release significantly more EVs than
control cells, suggesting that increased EV release is a mechanism
conducive to cell survival, following chemotherapeutic cell stress.
This is corroborated by Lehmann et al.14 who showed that
irradiation-induced senescent prostate cancer cells released more
EVs than controls.4
We hypothesise that the novel ability of cancer senescent
cells to remove ATPases, tubulins, Rabs, insoluble SASP factors,
integrins and annexins via EVs, in part conserves the senescent
phenotype. Intriguingly, 69 of 142 proteins in higher abundance in
TIS EVs are predicted activators of cell growth and proliferation,
suggesting that the removal of these proteins by TIS cells
represents a further potential mechanism to maintain their
senescent phenotype.
Our data show eight ATPases present in higher abundance in
TIS EVs compared with controls, including the 26S protease
regulatory subunits 6B and 10B (Table 1). The significance of these
subunits’ abundant expression in TIS EVs is potentially important,
implying a mechanism for retaining maximum ATP levels for the
survival and metabolic needs of the senescent cell. Moreover,
a sodium/potassium ATPase subunit displayed the highest
abundance in the MS profiles for the TIS EVs. This ATPase enables
the hydrolysis of ATP,33 suggesting that its removal via EVs may
Table 1. List of key proteins identified from MS analysis with an
increased abundance in TIS EVs vs control EVs
Fold change Anova (P)
Annexin
Annexin A7 191 0.030
Annexin A3 156 0.011
Annexin A5 15 0.002
Annexin A11 13 0.002
Annexin A2 9 0.001
Annexin A4 9 0.005
Annexin A1 6 0.0001
Annexin A6 6 0.002
ATP dependent
Sodium/potassium-transporting
ATPase subunit beta-1
633 0.017
CTP synthase 1 209 0.022
26S protease regulatory
subunit 6B
27 0.044
Potassium-transporting ATPase
alpha chain 2
16 0.004
Sodium/potassium-transporting
ATPase subunit alpha-1
11 0.005
Pre-mRNA-splicing factor
ATP-dependent RNA helicase
3 0.007
26S protease regulatory
subunit 10B
3 0.035
ATP-dependent RNA helicase A 3 0.050
Integrins
Integrin alpha-V n/a (protein was not
detected by MS in the
control samples)
6.76E-07
Integrin beta-3 6 0.020
Integrin beta-1 5 0.022
Tubulin
Tubulin alpha-1C chain 8 0.003
Tubulin beta chain 4 0.040
Tubulin alpha-1A chain 4 0.003
Tubulin beta-4A chain 4 0.007
Tubulin beta-2A chain 4 0.006
Tubulin beta-4B chain 3 0.004
Tubulin beta-3 chain 3 0.002
Tubulin alpha-1B chain 3 0.028
Tubulin beta chain 3 0.022
Rab proteins
Ras-related protein Rab-1A 10 0.018
Ras-related protein Rab-5C 5 0.010
Ras-related protein Rab-7a 4 0.021
Ras-related protein Rab-5A 3 0.029
Ras-related protein Rab-11A 3 0.010
Ras-related protein Rab-10 3 0.012
Insoluble SASP factors
Collagen alpha-1 (V) 15 0.025
Collagen alpha-2 (IV) 7 0.003
Laminin subunit alpha-5 4 0.025
Laminin subunit beta-1 3 0.018
Fibronectin 2 0.001
Abbreviations: EV, extracellular vesicle; MS, mass spectrometry;
SASP, senescence-associated secretory phenotype; TIS, therapeutic
induced senescence.
TIS cancer cells remove key proteins in EVs
EL Kavanagh et al
5
Oncogenesis (2017), 1 – 13
potentially conserve vital intracellular ATP resources crucial for
maintaining the metabolic demands of senescent cells and
therefore integral for senescent cell survival.34
In addition, our results show an increased abundance of eight
annexins within TIS EVs compared with controls (Table 1). We
hypothesise that annexin removal in EVs increases the survival
of TIS cells via their interactions in apoptotic, chemoresistant
and metastatic pathways. Specifically, Annexins A1 and A5 are
inhibitors of phospholipase A2 signalling,35,36 Annexin A5 is a
marker of apoptosis,37 whereas Annexin A6, A11 and A2 are
involved with cancer aggressiveness promoted by EVs,38
chemoresistance39 and EV-mediated angiogenesis and
metastasis,40 respectively. In summary, therefore, removal of
annexins via EVs is potentially advantageous to TIS survival.
Our data (Table 1) demonstrated an increase in nine different
subunits of tubulin within TIS EVs compared with controls.
Pathway analyses showed that the 'stathmin and breast cancer
resistance to anti-microtubule agents’ pathway' is upregulated in
TIS EVs. Normally, during mitosis, microtubule polymerisation
occurs, which is crucial for cell cycle progression. However,
stathmin promotes depolymerisation of microtubules. Differential
expression levels of stathmin leads to G2/M arrest.41 Interestingly,
protein phosphatase 2A and PP1 (protein phosphatase 1) regulate
the phosphorylation of stathmin,42 with PP1 present in higher
abundance in TIS EVs compared with controls (Supplementary
Table 1). Of note, the regulatory subunit 15B of protein
phosphatase 1 has been identified as a survival factor in breast
cancer.43 A recent study demonstrated that non-small cell lung
cancer cells, resistant to PTX, have high expression of stathmin
and inhibition of stathmin expression increased sensitivity to this
chemotherapeutic.44 Potentially therefore, the removal of tubulin
and PP1 (stathmin regulator) from TIS cells, could suggest that
microtubule dynamics have been switched from the stabilisation
effect of PTX to the depolymerisation effect of stathmin, crucial in
maintaining G2/M arrest and the chemoresistant and senescent
phenotypes.
In addition, there was an increase in three integrin subunits;
integrin beta-3, integrin beta-1 and integrin alpha-V, within TIS
EVs compared with controls. Interestingly, integrin beta-3 has
been associated with the progression of glioblastoma45 with
attenuated integrin beta-3 expression resulting in glioblastoma
cells becoming senescent.46 The integrin alpha-V-beta-3 complex
regulates cancer cell survival and proliferation by signalling
through the ERK1/ERK2 MAPK pathway in MDA-MB-231 breast
cancer cells.47 Moreover, a recent study has shown that integrin
beta-3 is a marker and regulator of senescence, activating the
TGF-β pathway leading to senescence in human primary
fibroblasts. Downregulation of integrin beta-3 has also been
shown to result in the reduction in oncogene-induced senescence
and TIS.48 Overall therefore, TIS cells may potentially remove the
integrin alpha-V-beta-3 complex in EVs to maintain the senescent
phenotype.
Figure 4. SDS–PAGE western blot validation of the increased abundance of Annexin V, Na/K ATPase and α-tubulin in the EVs derived from TIS
Cal51 cells compared with EVs derived from non-senescent non-treated controls. EVs isolated from TIS and control cells were immunoblotted
to validate the protein expression of annexin V, Na/K ATPase and α-tubulin from the MS data. CD63 and HSP70 were used as loading controls.
Densitometry was completed using Image J software (Fiji). All values are expressed as the mean of three independent experiments± s.e.m.
The limit of ± 1 skewness was set as normal distribution. Skewed data were transformed to Y= Log(Y) to fit a normal distribution. Results were
analysed using the Student’s t-test with significant differences having a *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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There was also an increase in 6 Rab proteins within TIS EVs
compared with controls (Table 1). Rabs modulate the release of
EVs from the multivesicular bodies. Rab-mediated EV trafficking
is important for migration, invasion and proliferation.49 K562
leukaemic cells express higher levels of Rab11 compared
with other Rabs, previously shown to modulate EV release.50
Figure 5. Pathway analysis of proteins in higher abundance in TIS EVs. (a) The top overrepresented pathways in TIS EVs by IPA. (b) The top
overrepresented pathways in control EVs by IPA. (c) Proteins from the data set (red) present in TIS EVs overlaid on the ‘Breast Cancer Regulation
by Stathmin 1’ pathway created by IPA. (d) Sixty-nine proteins from the data set (red) present in TIS EVs associated with cell proliferation,
generated by IPA. P-values reported for IPA results are calculated by IPA using a right-sided Fisher exact test for over-representation analysis
and Benjamini–Hochberg correction for multiple hypothesis testing correction.
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The increased release of EVs containing these Rabs suggests a
possible link to the increased release of EVs compared with
control cells.
In relation to the SASP, it is known that the insoluble
components can affect the physical properties of tissue structure
relaxing the extracellular matrix support. Moreover, the soluble
factors of the SASP in vivo, potentially allow tumour cells to
migrate through the extracellular matrix and metastasise.51
Of note, the insoluble SASP factors (fibronectin, collagen alpha-1
(IV) chain, collagen alpha-2(IV) chain, laminin subunit alpha-5 and
Figure 5. Continued.
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laminin subunit beta-1) (Table 1)53 were identified in EVs from TIS
Cal51 cells. Therefore, our findings support the proposal that
EVs derived from TIS cells not only represent a mechanism
of trafficking out unwanted cellular cargo but could equally
be utilising EVs to transport senescence/tumour promoting
proteins to neighbouring/distant sites to further promote the
senescent/tumorigenic phenotype. Urbanelli et al.52 similarly
suggest a role for EVs in the maintenance and promotion of the
senescent phenotype via the SASP.
MS analysis of EVs from control cells identified 32 proteins with
significantly increased fold change when compared with TIS EVs
(Supplementary Table 2). We hypothesise that these proteins are
crucial for TIS cell survival and therefore not released in EVs. Two
key pathways in higher abundance in control EVs were LXR/RXR
and FXR/RXR activation. Potentially, activation of these pathways
is crucial for the survival of TIS cells. LXR activation is known to
inhibit proliferation of breast cancer cells53 and FXR activation in
breast cancer cells results in cytotoxicity.54 Activated FXR can also
counteract the tumour promoting ability of cancer-associated
fibroblasts within the breast cancer microenvironment.55
Therefore, one might hypothesise that the removal of LXR
and FXR pathway components in control cell EVs suggests that
normal proliferation occurs. In contrast, TIS cells retaining
these components may allow them to maintain replicative
Figure 6. Fluorescence Intensity levels of the paclitaxel analogue Flutax-2 in EVs derived from TIS Cal51 cells. (a) Nanoparticle tracking analysis
(NTA) confirming EV isolation using Exospin. (b) Western blot confirmation of positive CD63 and negative calnexin markers. Note, owing to the
known glycosylation of CD63, band sizes of between 53 and 70 kDa are observed. (c) Quantification of positive SA-β-Gal staining in control
versus PTX treated and Flutax-2 (FLU)-treated cells. (d) Particle per ml concentration of EVs sized 0–995 nm was obtained using NTA and
normalised to the cell count. (e) Particle per ml concentration of exosomes sized 45–145 nm was obtained using NTA and normalised to the
cell count. (f) Fluorescent images of (i) control versus (ii) Flutax-2 (FLU)-treated cells showing Flutax-2 present within the cytoplasm. Images
were taken with a × 40 oil objective on a Leica DMI6000B epifluorescent microscope. Individual colour channels were merged and
pseudocolours were applied with Image J (Fiji) software. Any contrast adjustments were applied strictly across all channels in both images.
Scale bars represent 50 μm. (g) Graphical representation of the differing fluorescence levels detected in EVs derived from control, PTX treated
and Flutax-2 (FLU) treated Cal51 TNBC cells. In relation to the concentration of Flutax-2, the manufacturers recommend using × 10 the
concentration of paclitaxel (75 nM), therefore, 750 nM was used. https://www.thermofisher.com/order/catalog/product/P22310. All values are
expressed as the mean of three independent experiments± s.e.m. The limit of ± 1 skewness was set as normal distribution. Skewed data were
transformed to Y= Log(Y) to fit a normal distribution. Results were analysed using the Student’s t-test, with significant differences having a
*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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Figure 7. Treatment of TIS Cal51 cells with the exosome biogenesis inhibitor GW4869 results in a reduction in the number of SA-β-Gal-positive
cells and reduced growth potential. (a) Following 7 days culture of the Cal51 cells in control or senescent inducing conditions (PTX 75 nM), the
cells were then treated with control vehicle or 75 nM PTX and control vehicle or 5 μM GW4869 for 48 h. Cells were seeded at 100 000 cells/well
and stained using the SA-β-Gal staining kit (Cell Signalling) with 5 mg/ml X-gal. The percentage of positive SA-β-Gal staining was normalised
to the cell count in each condition. (b) Nanoparticle tracking analysis was carried out on each exosome sample isolated using Exospin and
normalised to the cell count. (c) Western blot appreciation of p21 expression on whole-cell lysates (WCLs) and EV confirmation using CD63-
positive and calnexin-negative expression. (d,i) Growth curve of all four conditions (control plus GW4869 C+, control minus GW4869 C−,
PTX plus GW4869 P+ and PTX minus GW4869 P−) over a 14-day time course. (ii) Expanded representation of (d,i) PTX plus GW4869 P
+ and PTX minus GW4869 P− over a 14-day time course. (e) Bar chart comparing cell counts of PTX minus GW4869 and PTX plus GW4869
treatments on days 9, 11 and 14. (f) Proposed Model: Cancer cells treated with chemotherapy signal apoptosis on their cellular membrane via
the annexin family of proteins and die. In contrast, therapeutic induced senescent (TIS) cells maintain viability via an upregulation of MDR1/P-
gp causing the efflux of chemotherapy, the release of substantially more EVs than control cells containing annexins, tubulins, ATPases,
insoluble SASP factors, 69 activators of proliferation and discarded chemotherapy (Flutax-2). All values are expressed as the mean of three
independent experiments± s.e.m. The limit of ± 1 skewness was set as normal distribution. Skewed data were transformed to Y= Log(Y) to fit
a normal distribution. Results were analysed using the Student’s t-test, with significant differences having a *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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stasis, maintain senescence and evade apoptosis by
chemotherapy.
Cal51 cells treated with the fluorescent PTX analogue Flutax-2
demonstrated removal of chemotherapy in EVs. The significantly
higher detected fluorescence in EVs derived from Flutax-2-treated
cells indicates that the chemotherapy is present within the EVs,
demonstrating a potential novel method by which senescent
cancer cells can remove chemotherapy. Whether this packaging
and removal of chemotherapy by the cells is a passive or active
process remains to be elucidated.
Previously, it has been shown that treatment with
GW4869 impairs EV formation and subsequent release from
macrophages.56 In our study, TIS cells treated with GW4869
showed significant reduction in SA-β-gal activity a key marker of
senescence. We also speculate that TIS cells utilise exosome
biogenesis to maintain their proliferative potential, as blocking
this with GW4869 lead to a reduction in proliferative recovery. The
lack of change in p21 following GW4869 treatment for 48 h may
reflect a time-dependent observation.
In conclusion, our study demonstrates that TIS cells release
significantly more EVs than control cells. Importantly, these EVs
not only contain Flutax-2 (PTX analogue) but also suggests a novel
mechanism by which TIS cells remove key proteins involved in cell
proliferation, ATP depletion, apoptosis and the SASP. These
findings may partially explain why cancer senescent cells remain
viable despite chemotherapeutic challenge and indeed can
continue to interact with the tumour microenvironment both
locally and distally.
MATERIALS AND METHODS
Cell culture
Cal51 TNBC cell line (p53 wild type) (DSMZ, Braunschweig, Germany, #ACC
302) was cultured in Dulbecco's Modified Eagle's Medium (Lonza, Visp,
Switzerland, #BE12-614 F) supplemented with 10% (v/v) FBS (foetal bovine
serum) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA, #10270-106)
and 1% (v/v) sodium pyruvate (Gibco, Thermo Fisher Scientific,
#S8636-100 ML) at 37 °C in a humidified atmosphere of 5% CO2.
Cal51 cells were authenticated by DDC Medical, Fairfield, OH, USA in
2015 and routinely tested negative for mycoplasma contamination.
PTX induced senescence
Cells were treated for 7 days with 75 nM PTX (Sigma-Aldrich, St Louis, MO,
USA, #T7402-1MG). Senescence was confirmed through appreciation of
SA-β-Gal activity, Ki67-negative immunohistochemistry staining, p21 and
p16 protein expression using western blot analysis and cell cycle
evaluation using flow cytometry.
Flutax-2
‘Flutax-2’, an Oregon Green 488 PTX conjugate (Supplementary Figure 1B)
(Thermo Fisher Scientific, #P22310), fluorescently labels the tubulin
cytoskeleton. Cal51 cells were treated for 5 days with 75 nM PTX to induce
senescence. On day 5, the treatment was changed to EV-depleted-serum
medium with 750 nM Flutax-2 for 48 h. This 10 × higher concentration of
Flutax-2 compared with PTX (75 nM) is the recommended dose as per
manufacturers recommendations. EVs were isolated using Exospin,
(Cell Guidance Systems, Cambridge, UK, #EX-01) characterised and profiled
using NTA (NanoSight NS300; Malvern, Malvern, UK) with EV Flutax-2
fluorescence quantified at 488 nm on a microplate reader (Molecular
Devices, Spectramax, Sunnyvale, CA, USA).
SA-β-Gal staining assay
TIS cells were seeded at 1 × 105 cells/ml, cultured for 24 h, fixed and
stained using the SA-β-Gal staining kit, 5 mg/ml (Cell Signalling
Technology, Danvers, MA, USA, #9860), incubated for 16 h, imaged using
a light microscope (Olympus model CKX41, Tokyo, Japan) and enumerated
for SA-β-Gal positivity using Image J software (FIJI).
Immunohistochemistry for cultured cell lines
Cells were seeded at 1 × 105 cells/ml, fixed with ice-cold methanol (Sigma-
Aldrich, #24229-2.5L-R) and stained using the Novolink Polymer Detection
(Leica Biosystems, Wetzlar, Germany, #RE7140-CE). Cells were stained for
Ki67 (1:1000) (Thermo Fisher Scientific, #MA5-15690), counterstained using
haematoxylin (Reagecon, Shannon, County Clare, Ireland, #RBA-4201-00A),
mounted onto slides using Mowiol 4–88 (Sigma-Aldrich, #81381) and
imaged with a × 60 oil immersion lens (Nikon Eclipse E600 microscope,
Tokyo, Japan).
Cell cycle assay
A total of 1 × 106 cells/ml were fixed in 1 ml of ice-cold 70% methanol
(Sigma-Aldrich, #24229-2.5L-R), washed in PBS (phosphate-buffered saline)
(Oxoid, Basingstoke, Hampshire, UK, #BR0014G), treated with RNAse
0.2 mg/ml (Sigma-Aldrich, #R6513-10MG) and stained with propidium
iodide 50 μg/ml (Molecular Probes Life Technologies, Eugene, OR, USA,
#P1304MP) for 30 min at 37 °C with agitation. The cells were washed once
more with PBS and resuspended in 500 μl PBS. Samples were analysed
using a BD Accuri C6 (BD Biosciences, San Jose, CA, USA) with the default
configuration, 20 000 single cells were recorded per sample and the results
were analysed using DeNovo Software FCS Express RUO Version 6.
SDS–PAGE and western blotting
Sodium dodecyl sulphate polyacrylamide gel electrophoresis and western
blotting were performed as described previously.57,58 The following
antibodies were used: p16 (Santa Cruz Biotechnology, Dallas, TX, USA,
#sc-56330), MDR1/P-gp (Santa Cruz Biotechnology, #sc-1517), calnexin
(Santa Cruz Biotechnology, #sc-80645), α-tubulin (Santa Cruz Biotechnol-
ogy, #sc-32293), annexin V (Abcam, #ab14196), CD63 and HSP70 (System
Biosciences, Palo Alto, CA, USA, #EXOAB-CD63A-1), p21 (BD Biosciences,
#556430), GAPDH (Cell Signalling, #5174P) and Na/K ATPase (Novus
Biologicals, Littleton, CO, USA #NB300-146). The differential CD63 bands
potentially represents either differential glycosylation59 or the isolation
method used to harvest EVs.60 Densitometry was completed to determine
the expression of proteins. Densitometry was completed using Image J
software with all results normalised to the loading control.
EV isolation
Cells grown for EV harvesting purposes were cultured prior to isolation in
media supplemented with bovine EV-depleted FBS for 48 h. FBS was
depleted of EVs by ultracentrifugation at 120 000× g for 16 h at 4 °C. The
RCF average was calculated using the Beckmann Coulter rotor calculator
for the Beckman Coulter Optima L-100 XP Ultracentrifuge and Beckman
Coulter Type 70Ti rotor. EV-depleted FBS media was conditioned for 48 h
then collected and centrifuged at 300× g at 4 °C for 10 min followed by
2000× g at 4 °C for 20 min to ensure cellular debris removal. The
supernatant was filtered using a 0.22 μm syringe filter (Millipore, Billerica,
MA, USA, #SLGP033RS). For isolation using the ultracentrifugation protocol,
the supernatant was sealed in an ultracentrifugation tube (Beckman
Coulter, Brea, CA, USA, #342414), and subsequently ultracentrifuged twice
at 120 000× g for 1 h 15 min at 4 °C. For isolation using Exospin the
manufacturer’s guidelines were followed (Cell Guidance Systems, #EX-01).
EV counts represent values normalised to cell count.
NanoSight NS300 EV profiling
EV samples were run using the standard measurement procedure at 25 °C
with a constant syringe infusion rate of 50 as per the NanoSight NTA 3.1
Software (Malvern). The data for each sample were obtained from 10
independent 60 s video captures on the NS300, analysed and normalised
to final cell counts for each condition.
Quantitative proteomic profiling by label-free liquid
chromatography–MS/MS analysis
EV pellets were solubilised in 8 M urea/50 mM NH4HCO3/0.1% ProteaseMax
using sonication, with resultant protein levels quantified using a Bradford
assay. Following dithiothreitol reduction and iodoacetic acid-mediated
alkylation, a double digestion was performed using Lys-C (for 4 h at 37 °C)
and Trypsin (overnight at 37 °C) on 5 μg of protein. The samples were
desalted prior to analysis using C18 spin columns (Thermo Scientific) and
500ng was loaded onto an Ultimate 3000 NanoLC system
(Dionex Corporation, Sunnyvale, CA, USA) coupled to a Q-Exactive mass
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spectrometer (Thermo Fisher Scientific). The raw data were analysed using
Progenesis QI for Proteomics software (version 3.1; Non-Linear Dynamics,
a Waters company, Newcastle upon Tyne, UK) as previously described,61
with following modifications: the filter mass peaks with charge states from
+1 to+6 was applied to the MS/MS data files, peptides were identified
using taxonomy: Homo sapiens in the SwissProt database and peptides
with XCorr scores41.9 for +1 ions,42.2 for +2 ions and43.75 for +3 ions
or more (from Sequest HT) were selected.
Treatment of Cal51 TNBC cells with the exosome biogenesis
inhibitor GW4869
GW4869 is a cell permeable, potent inhibitor of the biogenesis of
exosomes via the inhibition of N-SMase.56 Cal51 cells grown in both
control and senescence inducing conditions were subsequently treated
with control vehicle or GW4869, 5 μM (Sigma-Aldrich, #D1692) for 48 h.
Cells were trypsinised and seeded for the SA-β-gal enumeration. Media
was collected and EVs isolated with ExoSpin.
Cell proliferation assay
Cells were seeded at a density of 5 × 105 cells/ml in six-well plates. Cells
were treated with PTX for 7 days to induce senescence followed by
GW4869 treatment, 5 μM (Sigma-Aldrich, #D1692) for 48 h. Cells were
subsequently trypsinised, stained with trypan blue and counted using a
haemocytometer at 0, 1, 2, 4, 7, 9, 11 and 14 day timepoints.
Pathway analysis
Pathway, interaction network and functional enrichment analyses were
performed with the proteins identified in EVs using IPA (www.ingenuity.
com) software (Ingenuity Systems, Qiagen) and InnateDB (http://www.
innatedb.com). P-values reported for IPA results are calculated by IPA using
a right-sided Fisher exact test for over-representation analysis and
Benjamini–Hochberg correction for multiple hypothesis testing correction.
Statistical analyses
All values are expressed as the mean of three independent experiments ±
s.e.m. The limit of ± 1 skewness was set as normal distribution. Skewed
data were transformed to Y= Log(Y) to fit a normal distribution. Results
were analysed using the Student’s t-test, unless as otherwise stated in
the quantitative proteomic profiling by label-free liquid chromatography–
MS/MS analysis and pathway analysis sections. Significant differences are
defined as *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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